Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

IELSG-47

Coordinating investigator

Prof. Dr. med.
Emanuele
Zucca
Istituto Oncologico della Svizzera Italiana (IOSI)
+41 91 811 91 47 / +41 91 811 80 49

For further information on the IELSG-47 trial, please consult the website www.ClinicalTrials.gov.

Clinics

All trials